- Home
- NEO vs CPRI Comparison
NEO vs CPRI Comparison
Compare NEO & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEO | CPRI |
|---|---|---|
| Founded | 2001 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | 11200 |
| Industry | Precision Instruments | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2008 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NEO | CPRI |
|---|---|---|
| Price | $16.90 | $20.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $23.40 | $23.17 |
| AVG Volume (30 Days) | 1.9M | ★ 3.6M |
| Earning Date | 10-28-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.40 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $3,474,000,000.00 |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $9.68 | $2.45 |
| P/E Ratio | ★ N/A | $24.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.07 | $12.40 |
| 52 Week High | $20.15 | $28.27 |
Technical Indicators
Market Signals| Indicator | NEO | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 75.50 |
| Support Level | $15.73 | $16.82 |
| Resistance Level | $17.19 | $21.98 |
| Average True Range (ATR) | 0.86 | 0.85 |
| MACD | -0.01 | 0.53 |
| Stochastic Oscillator | 29.78 | 84.33 |
Price Performance
Historical ComparisonAbout NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 600 company-owned stores, wholesale partners, and online. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold through third-party retailers, e-commerce platforms, and in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.